Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease
A Gershon, R Croxford, A Calzavara, T To… - JAMA internal …, 2013 - jamanetwork.com
Importance Chronic obstructive pulmonary disease (COPD) is a common and deadly
disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for …
disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for …
Combination bronchodilator therapy in COPD
SI Rennard - Chest, 1995 - journal.chestnet.org
A number of agents are available for the treatment of patients with COPD. For agents whose
suggested mode of action is quite distinct (Table 1), a combination of various agents in a …
suggested mode of action is quite distinct (Table 1), a combination of various agents in a …
Physician perceptions and management of COPD
S Kesten, KR Chapman - Chest, 1993 - Elsevier
To assess awareness and understanding of obstructive airway diseases by primary-care
physicians, the authors surveyed a randomly selected population of 75 primary care …
physicians, the authors surveyed a randomly selected population of 75 primary care …
Prevalence and treatment of chronic obstructive pulmonary disease (COPD) in the United States
AI Biener, SL Decker, F Rohde - Jama, 2019 - jamanetwork.com
In 2014 and 2015, more than 6% of adults aged 40 years or older reported having been
diagnosed with chronic obstructive pulmonary disease (COPD). Although the prevalence of …
diagnosed with chronic obstructive pulmonary disease (COPD). Although the prevalence of …
Intensive intervention to improve outcomes for patients with COPD
ST Rinne, PK Lindenauer, DH Au - JAMA, 2018 - jamanetwork.com
Part of the success of the intervention in this study also may relate to the creation of a team,
partnering patients, caregivers, and clinicians, which was a central theme in the study …
partnering patients, caregivers, and clinicians, which was a central theme in the study …
Characterization of chronic obstructive pulmonary disease prescribing patterns in the United States
SE Petite - Pulmonary Pharmacology & Therapeutics, 2018 - Elsevier
Background Chronic obstructive pulmonary disease (COPD) is the third-leading cause of
death in the United States. Guideline recommendations for medication therapy include the …
death in the United States. Guideline recommendations for medication therapy include the …
Addition of anticholinergic solution prolongs bronchodilator effect of β2agonists in patients with chronic obstructive pulmonary disease
DC Levin, KS Little, KR Laughlin, JM Galbraith… - The American journal of …, 1996 - Elsevier
A randomized, double-blind, placebo-controlled clinical trial was designed to assess the
safety, efficacy, and duration of the bronchodilation resulting from the addition of 500 μg of …
safety, efficacy, and duration of the bronchodilation resulting from the addition of 500 μg of …
[HTML][HTML] Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
DMG Halpin, M Kerkhof, JB Soriano, H Mikkelsen… - Respiratory …, 2016 - Springer
Background Management guidelines of chronic obstructive pulmonary disease (COPD) are
mainly based on results of randomised controlled trials (RCTs), but some authors have …
mainly based on results of randomised controlled trials (RCTs), but some authors have …
Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease
P Rogliani, L Calzetta, MG Matera… - Expert Opinion on …, 2019 - Taylor & Francis
Introduction: Chronic obstructive pulmonary disease (COPD) therapy includes a multi-
dimensional approach, taking into account both symptoms of the patient and the number of …
dimensional approach, taking into account both symptoms of the patient and the number of …
Bronchodilator effect of an inhaled combination therapy with salmeterol+ fluticasone and formoterol+ budesonide in patients with COPD
M Cazzola, P Santus, F Di Marco, B Boveri… - Respiratory …, 2003 - Elsevier
In the present trial, we compared the broncholytic efficacy of the combination therapy with 50
μg salmeterol+ 250 μg fluticasone and 12 μg formoterol+ 400 μg budesonide, both in a …
μg salmeterol+ 250 μg fluticasone and 12 μg formoterol+ 400 μg budesonide, both in a …